|
Vaccine Detail
ALVAC-HIV-2- env/gag/pol |
Vaccine Information |
- Vaccine Name: ALVAC-HIV-2- env/gag/pol
- Target Pathogen: Human Immunodeficiency Virus
- Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
- Vaccine Ontology ID: VO_0004737
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- env
gene engineering:
- Type: Recombinant vector construction
- Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
- Detailed Gene Information: Click Here.
- gag
gene engineering:
- Type: Recombinant vector construction
- Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Monkey Response
- Vaccination Protocol: Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: 7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001).
- Efficacy: Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).
|
References |
Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].
|
|